Call for Abstracts
Submission Period
March 2 (Mon) – April 28 (Tue), 2026 (JST)
Presentation Type & Time
Only on-site (in-person) presentations will be accepted.
Only oral presentations will be accepted; no poster presentations will be offered.
| Presentation type |
|---|
| Symposium Each symposium will last 75–90 minutes. The allocation of time for presentations, Q&A, and discussion will depend on the number of accepted abstracts. |
| International Session Presentation Time (Tentative)：6 minutes Q&A：2 minutes |
Abstract Submission Guidance
All presentations must be conducted in English, including the abstract, presentation slides.
Please ensure that your abstract and all presentation materials are prepared in English.
- Abstract title is up to 200 characters.
- Abstract body is up to 1,800 characters.
- Up to 20 co-authors including the first author.
- Up to 20 affiliations including affiliation of the first author.
- The abstract must not contain any graphics, tables, pictures, or other types of figures.
Ethics Review
Our society established in 2017 the Ethical Guidelines for Medical and Health Research Involving Human Subjects in accordance with the notifications issued by the Ministry of Education, Culture, Sports, Science and Technology (MEXT) and the Ministry of Health, Labour and Welfare (MHLW).
These Guidelines stipulate that “Researchers and related personnel must comply with applicable laws and regulations and relevant guidelines, and must conduct research appropriately in accordance with a research protocol that has been reviewed and approved by an Ethics Review Committee (or, in the case of specified clinical research, a Certified Review Board) and authorized by the head of the research institution.”
When submitting an abstract, applicants will be required to declare whether their research is subject to ethical review.
Applicants will be required to respond to the following declaration items in the system at the time of abstract submission.
The Japan Society of Coloproctology
Journal of the Anus, Rectum and Colon
Ethics Review/Checkbox
Conflict of Interest Disclosure
At the time of abstract submission, for the lead author and all co-authors, please disclose any COI (Conflict of Interest) status related to companies, organizations, or entities associated with the presentation topic within the past three years from the time of submission, by self-declaration for each author.
| ①Honoraria | $10,000 or more per year from one company or organization. |
|---|---|
| ②Stock or stock options | $10,000 or more per year or holding 5% or more of shares in one private company |
| ③Royalties or licenses | $5,000 or more per year for one patent |
| ④Lecture fees | $5,000 or more per year from one company or organization |
| ⑤Manuscript fees | $5,000 or more per year from one company or organization |
| ⑥Research funding | $10,000 or more per year of research funding including funding for collaborative research, funded research, and drug trials paid by one company or organization |
| ⑦Scholarship fund | $10,000 or more per year provided by one company or organization to a disclosing party, his/her course/class, or laboratory. |
| ⑧Belonging to endowed chair by business | － |
| ⑨Travel fees, gifts, and others | $500 or more per year from one company or organization |
Notification of acceptance
All submitted abstracts will undergo peer review.
Notification of acceptance will be sent via e-mail to the first author by the end of July, 2026.
Presenter Change and Withdrawal Policy
As a general rule, the first author shall be responsible for presenting the accepted abstract.
However, in the event that the first author is unable to present due to unforeseen circumstances, the following measures shall apply. Please contact us at reg_jscp81@c-linkage.co.jp .
Please note that failure to present without prior notification shall result in withdrawal of the abstract.
Substitute Presentation by a Co-Author
A substitute presentation is allowed only if all of the following conditions are met:
-The substitute presenter is a co-author who can respond to questions during the presentation.
-The presentation credit remains with the registered first author, and the substitute co-author agrees that it will not count as their own academic achievement.
＊Information in the online abstract, abstract app, or J-STAGE will not be modified.
The substitute presenter must clearly state at the beginning of the presentation that they are presenting on behalf of the first author.
Abstract Withdrawal
Abstracts that are withdrawn will not be recognized as presentation achievements.
Abstracts that have been published in the online program or abstract app will be removed.
However, the timing of removal depends on the date of the abstract withdrawal request.
In addition, withdrawn abstracts will not be published on J-STAGE after the conference.
Personal information
Personal information provided during abstract submission will not be used for any purpose other than society membership management and academic presentation, and will be strictly protected by the secretariat.
Abstract Submission
After abstract submission, a confirmation email will be automatically sent to your email address.
Symposium - Chair’s Remarks
| Symposium |
|---|
SY-C : Cutting edge of endoluminal/ transanal surgery for colorectal cancer
- Chair：
Kotaro Maeda Medical Cooperation Himawariseishinnkai Oumeimai Hospital
Motohiko Kato Center for Diagnostic and Therapeutic Endoscopy, Keio University School of Medicine
Recent advances in colorectal minimally invasive therapy have expanded both endoluminal and transanal approaches. The improvement of resection technique of endoscopic submucosal dissection (ESD) and secure suturing have enabled deeper-layer techniques, including per anal endoscopic myectomy (PAEM). Meanwhile, transanal surgical techniques such as transanal endoscopic surgery continue to evolve, improving precision and safety. In this session, we will discuss indications, technical innovations, and current challenges, and explore how endoscopic and surgical strategies can complement each other to optimize patient-centered colorectal treatment.
SY-F : Recent advances in surgery for colorectal diseases
- Chair：
Kay Uehara Department of Gastroenterological Surgery, Nippon Medical School
Welcome to the “Recent Advances in Surgery for Colorectal Diseases” symposium at the 81st JSCP Annual Meeting in Nagasaki.
This session is designed to showcase global progress in colorectal surgery, with a focus on innovation, technique, and clinical outcomes. As we embrace a more collaborative and inclusive scientific community, we invite contributions from both domestic and international surgeons, aiming to stimulate cross-border dialogue and future partnerships.
Join us in exploring the next frontiers of colorectal disease management.
SY-G : Gut Microbiota and Colorectal Diseases: A Future Unlocked by the Microbiome
- Chair：
Hiroto Miwa Kawanishi City Medical Center
Tomohisa Takagi Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine
As research on the gut microbiome continues to rapidly evolve, innovative findings in this field are transforming our understanding of colorectal diseases, from basic mechanisms to clinical applications. This symposium aims to provide an international platform for researchers and clinicians to share cutting-edge research, novel methodologies, and emerging therapeutic strategies related to the gut microbiota and colorectal disorders.
We warmly welcome submissions covering a wide range of topics, including but not limited to: basic science, translational research, clinical studies, and microbiome-based interventions. We especially encourage young investigators and early-career researchers to submit their original work and actively participate in this scientific exchange. We sincerely look forward to receiving your valuable contributions and to welcoming you to this exciting session.
International Session Category
| （I）Category A |
|---|
| A01 | Early-stage Colon Cancer |
|---|---|
| A02 | Early-stage Rectal Cancer |
| A03 | Advanced Colon Cancer |
| A04 | Advanced Rectal Cancer |
| A05 | Metastatic and Recurrent Colorectal Cancer |
| A06 | Hereditary Colorectal Cancer and Polyposis |
| A07 | Other Colorectal Malignancies |
| A08 | Benign Colorectal Tumors |
| A09 | Ulcerative Colitis |
| A10 | Crohn’s Disease |
| A11 | Other Inflammatory Bowel Diseases |
| A12 | Functional Bowel Disorders |
| A13 | Other Benign Colorectal Diseases |
|---|---|
| A14 | Bowel Obstruction |
| A15 | Rectal Prolapse and Pelvic Organ Prolapse |
| A16 | Constipation, Fecal Incontinence, and Defecatory Disorders |
| A17 | Hemorrhoids |
| A18 | Anal Fistula |
| A19 | Anal Fissure |
| A20 | Anorectal pain |
| A21 | Other Anal Diseases |
| A22 | Stoma Care and Management |
| A23 | Colorectal Diseases in the Elderly |
| A24 | Others |
| （II）Category B |
|---|
| B01 | Examinations and Diagnosis |
|---|---|
| B02 | Medical Treatment |
| B03 | Endoscopic Treatment |
| B04 | Surgical Treatment |
| B05 | Minimally Invasive Surgery |
| B06 | Chemotherapy and Immunotherapy |
| B07 | Radiation Therapy |
|---|---|
| B08 | Pathology and Basic Research |
| B09 | Case Reports (≤5 Cases) |
| B10 | Postoperative Complications and Perioperative Management |
| B11 | Metabolism, Nutrition, and Palliative Care |
| B12 | Others |
| （Ⅲ）Medical Department |
|---|
| C01 | Gastroenterology |
|---|---|
| C02 | Colorectal Surgery |
| C03 | Proctology |
| C04 | Gastroenterology & Colorectal Surgery |
| C05 | Gastroenterology & Proctology |
|---|---|
| C06 | Colorectal Surgery & Proctology |
| C07 | Gastroenterology, Colorectal Surgery & Proctology |
| （Ⅳ）Subcategory |
|---|
| D01 | Not applicable |
|---|---|
| D02 | Latest Evidence in the Diagnosis and Treatment of Functional Gastrointestinal Disorders |
| D03 | Current Clinical Practice in Chronic Constipation |
| D04 | Endoscopic Resection for Colorectal Polyps |
| D05 | Surveillance after Colorectal Endoscopic Treatment |
| D06 | Colonoscopy and Endoscopic Treatment in Patients on Antithrombotic Therapy |
| D07 | Clinical Application and Latest Data on Colon Capsule Endoscopy |
| D08 | Colorectal Endoscopic Submucosal Dissection (ESD) |
| D09 | Treatment Strategies for cT1bN0M0 Colorectal Cancer |
| D10 | Endoscopic Management in Elderly Patients |
| D11 | Chemoprevention of Colorectal Cancer |
| D12 | Colorectal Cancer Screening |
| D13 | Chemotherapy for Advanced Colorectal Cancer |
| D14 | Cancer Care in Frail Elderly Patients |
| D15 | Medical Treatment of Ulcerative Colitis |
| D16 | Medical Treatment of Crohn’s Disease |
| D17 | Medical Treatment of Inflammatory Bowel Disease |
| D18 | Inflammation-Associated Carcinogenesis |
| D19 | Pouchitis: Pathophysiology and Optimization of Medical–Surgical Collaboration |
| D20 | Colonic Diverticular Disease |
| D21 | Infectious Enterocolitis: Differential Diagnosis, Risk Factors for Severity, and Treatment Strategies |
| D22 | Recent Advances and Clinical Algorithms for Ischemic Colitis |
| D23 | Artificial Intelligence in Endoscopy |
| D24 | Artificial Intelligence in Laparoscopic Surgery |
| D25 | Treatment Outcomes of Colorectal Cancer with Abscess Formation: Surgery First or Systemic Therapy First? |
| D26 | Outcomes of Colorectal Cancer with Pancreatic Invasion |
| D27 | Outcomes of Surgical Resection for Para-aortic Lymph Node Metastases |
| D28 | Surgical Resection for Peritoneal Recurrence after Colorectal Cancer Surgery (Excluding Isolated Ovarian Metastases) |
| D29 | Is Adjuvant Therapy Necessary for pT1N(+) Colorectal Cancer? |
| D30 | Outcomes of Brain Metastases from Colorectal Cancer |
| D31 | Outcomes of Local Therapies Other than Resection for Lung Metastases from Colorectal Cancer |
| D32 | Management of Chylous Ascites after Colorectal Cancer Surgery |
|---|---|
| D33 | Desmoid Tumors Associated with Familial Adenomatous Polyposis |
| D34 | Treatment Outcomes of Fistula-Associated Anal Cancer |
| D35 | Rectal and Anal Canal Cancer with Pagetoid Spread |
| D36 | Treatment Outcomes of Rectal Neuroendocrine Tumors |
| D37 | Treatment Outcomes of Rectal Gastrointestinal Stromal Tumors |
| D38 | Treatment Outcomes of Stercoral Perforation of the Colon |
| D39 | Benefits and Limitations of Neoadjuvant Chemotherapy for Colorectal Liver Metastases |
| D40 | Surgical Treatment for Stoma Prolapse |
| D41 | Treatment Outcomes of Acute Appendicitis with Panperitonitis |
| D42 | Outcomes of Different Reconstruction Methods after Intestinal Resection in Crohn’s Disease |
| D43 | Long-term Outcomes of Surgical Procedures Other than Total Colectomy (Including IRA) for Ulcerative Colitis |
| D44 | Surgical Treatment for Inguinal Lymph Node Metastases |
| D45 | Case Report: Troubleshooting in Robot-Assisted Colorectal Surgery |
| D46 | Case Report: Challenging Surgical Cases |
| D47 | Case Report: Surgical Treatment of Malignancies with Major Vascular Invasion |
| D48 | Case Report: Rare Small Intestinal Diseases Requiring Surgical Treatment |
| D49 | Treatment of Rectal Prolapse and Pelvic Floor Descent: Techniques and Outcomes (Including Rectocele) |
| D50 | Surgical Techniques for Hemorrhoids: Evolving Approaches |
| D51 | Latest Advances in the Treatment of Anal Fissures |
| D52 | Surgical Techniques for Complex Anal Fistulas: Evolving Approaches |
| D53 | Surveillance in Patients with Long-standing IBD: Timing and Methods (Including Anal Lesions and Postoperative Cases) |
| D54 | Management Strategies for Colorectal and Proctology-Focused Medical Institutions in the Current Crisis |
| D55 | The forefront of fecal incontinence treatment |
| D56 | Pregnancy, childbirth and anal diseases |
| D57 | Strategies for the anal diseases in patients receiving anticoagulants and antiplatelet drugs (including perioperative period) |
| D58 | Hospital (clinic) management utilizing AI, ICT, and RPA |
| D59 | Case Report: Severe complications after anorectal surgery |
| D60 | Case Report: Anal lesions that were difficult to diagnose |
| D61 | Irritable bowel syndrome |
Contact
If you have any question about the registration, please contact us at the address below.
Secretariat of the 81st Annual Meeting of the Japan Society of Coloproctology.
c/o Convention Linkage, Inc.
Email: reg_jscp81@c-linkage.co.jp